A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer
Stopped Based on the safety events and evidence of biologic activity without sustained clinical responses the Sponsor finds the risk/benefit analysis unfavorable for patients and has terminated the study.
Conditions
- Metastatic Castration-resistant Prostate Cancer
Interventions
- BIOLOGICAL: CART-PSMA-TGFβRDN
- DRUG: Cyclophosphamide
- DRUG: Fludarabine
- DRUG: Anakinra
Sponsor
Tceleron Therapeutics, Inc.